Immunoisolation is the separation of transplanted cells from cells of the immune system using a semipermeable membrane. Using one such immunoisolation capsule-the TheraCyte  device-we have assessed the survival of encapsulated xenogeneic tissue in vivo as well as the contribution of CD4 +ve T cells to encapsulated xenograft rejection. The foreign body reaction to the TheraCyte  capsule in vivo was assessed by transplanting empty capsules into normal mice. These capsules elicit a foreign body response by the host animal. Encapsulated CHO, NIT-1, and PK-15 cells were placed in culture and in immunodeficient mice to investigate their growth characteristics in the TheraCyte  device. These cell lines survive both in culture and in immunodeficient SCID mice. Xenogeneic PK cells were also transplanted into normal C57BL/6 mice. These cells do not survive in normal mice despite the absence of direct contact between infiltrating and encapsulated cells. In addition, the survival of encapsulated cells in mice treated with a single dose of anti-CD4 antibody was examined. This was assessed using two systems: 1) histological analysis of capsule sections; 2) a quantitative luciferase reporter system using PK cells transfected to express luciferase. In both cases, anti-CD4 antibody contributed to prolonged encapsulated xenogeneic cell survival. Encapsulated xenogeneic cells survive in immunodeficient mice but not normal mice. Treatment of normal mice with anti-CD4 antibody results in prolonged survival of xenogeneic cells that can be measured using a luciferase reporter system. These results highlight the contribution of CD4 +ve T cells to encapsulated xenograft rejection.
INTRODUCTION
Despite some success of immunoisolation devices, an inflammatory response can often be detected surround-Immunoisolation is the separation of living cells from ing the transplanted capsule and this response can medithe cells of the immune system by a synthetic, permeate the nonspecific destruction of tissues inside the deable membrane. The aim of this technique is to allow vice (6). In addition, a rejection response against the free exchange of nutrients, gases, and proteins between encapsulated cells can still occur. In particular, xenogeblood or plasma and the encapsulated cells, while at the neic cells are rapidly rejected in capsules that can mainsame time excluding the host immune cells from direct tain prolonged survival of allogeneic cells (4,6,15,16) interaction with the encapsulated cells. Such encapsulaand this response has been shown to be due to CD4 +ve T tion devices could be used to treat diseases caused by cells activated via the indirect antigen presentation pathloss of a specific cell function.
way (16) . CD4 +ve T cells have also been shown to be A variety of cell types have been encapsulated in imcritical for the initiation of rejection responses to nonenmunoisolation devices for the treatment of a range of capsulated xenogeneic tissue, and continuous treatment diseases. These cells include adrenal chromaffin cells with anti-CD4 antibody is a potent immunosuppressive for the treatment of chronic pain (1, 21) , pancreatic islets strategy that allows prolonged xenograft survival (17, for the treatment of insulin-dependent diabetes mellitus 22) . (13, 19, 23) , and cells engineered to secrete human One particular immunoisolation device is the Theragrowth hormone and human factor IX, for the treatment Cyte  capsule, produced by Baxter Healthcare (7). This of dwarfism and hemophilia, respectively (9, 12) . planar device has a bilayer membrane. The membrane 184 MCKENZIE ET AL.
architecture of this device has been shown to increase membranes. TheraCyte  capsules were sterilized using 100% and 70% ethanol washes before three 20-min vascularization around the capsule to avail appropriate oxygen and nutrient supply (5). Isografts and allografts washes with sterile normal saline. The appropriate cell suspension (2 × 10 6 cells) was taken up in a Hamilton have been shown to survive after 1 year in these devices (28) . Long-term, high-level expression of human factor syringe with a blunt 26-gauge needle and the needle inserted into the device port leading into the capsule lu-IX protein from transfected cells in the TheraCyte  capsule can be achieved in rodents (7). Transplantation of men. Cells were injected into the capsule followed by silicon adhesive to seal the device port entrance. The TheraCyte  devices containing rat islets, into chemically induced diabetic mice, also resulted in a reversal of hy-protruding device port was removed and the capsule was implanted into the peritoneal cavity of anesthetized perglycemia before the removal of the capsules 8 weeks after transplantation (26) .
mice. Using the TheraCyte  capsules we have examined Transplantation of Immunoisolation Capsules whether an encapsulated xenogeneic cell line can sur-Mice were anesthetized with xylazine/ketamine, IP, vive in vivo in mice. In addition, we have assessed the 0.12 ml/mouse [stock: 10 ml normal saline, 1 ml Romcontribution of CD4 +ve T cells to the rejection response pun (xylazine, Bayer Australia Ltd, Pymble, NSW), 1 against encapsulated tissue using an anti-CD4 antibody.
ml ketamine (Parnell Laboratories, Alexandria, NSW)].
MATERIALS AND METHODS
The peritoneal cavity was opened with a midline inci-Animals sion and the capsule was placed into this site. The incision in the peritoneal wall was closed using surgical su-CB.17 SCID (H-2 d ) and C57BL/6 (H-2 b ) mice were tures (Dynek, Australia) while the skin incision was bred in specific pathogen-free conditions and maintained closed with surgical clips. Mice were monitored until at the animal housing facilities of The Walter and Eliza recovery from the anesthetic. Hall Institute. Mice were used between 6 and 10 weeks of age. The institutional ethics committee approved all Flow Cytometry animal studies.
A sample of peripheral blood from anti-CD4 anti-Antibody body-treated mice was labeled with rat anti-mouse CD4 antibody conjugated to FITC (Caltag Laboratories, Bur-GK1.5 is a rat anti-mouse CD4 antibody (IgG2b) lingame, CA) for 30 min. Cells were screened using the (10). Antibody was purified from mouse ascites using FACScan Flow Cytometer (Becton Dickinson, San Jose, protein A-Sepharose. Mice were treated intraperitone-CA). Twenty thousand cells were counted. Dead cells ally with a single dose of 300 µg of antibody on day −1 were excluded and the live cells gated for lymphocytes. before capsule transplantation.
PK cells were detected using low forward scatter and Cell Lines side scatter settings plus anti-mouse MHC class I antibody (M142), which stains mouse but not pig cells. PK-15 (designated PK) is a pig kidney cell line de-Total blood cell counts were determined from periphrived from an adult pig (30) that was cultured in SMEM/ eral blood samples using a hemocytometer. 1% NEAA + 7% FCS. CHO cells, an ovary cell line derived form a Chinese hamster (20) , were cultured in Transfection of PK Cells With a Luciferase Construct DME + 10% FCS. NIT-1 cells (designated NIT) are an
The luciferase construct used was previously deinsulinoma cell line derived from a transgenic NOD/Lt scribed (3). For stable transfection, 20 µg of luciferase mouse bearing the SV40 early region gene under the rat plasmid was electroporated into 5 × 10 6 PK cells at 1000 insulin II promoter (11). NIT cells were cultured in V, 25 µF using Gene Pulser II (Bio-Rad, Hercules, CA). DME/NEAA + 10% FCS. All cells were harvested using Transfected cells were selected with 0.6 mg/ml Hygroa Trypsin solution. The cells (2 × 10 6 ) were injected into mycin (Boehringer-Mannheim, Mannheim, Germany) each immunoisolation capsule before transplantation. and cloned by limiting dilution. Screening of superna-Immunoisolation Capsules tants for luciferase production was performed using a luciferase expression assay. The TheraCyte  capsule (Baxter Healthcare, Deerfield, IL) has a capacity of 20 µl within a bilayer mem-Luciferase Activity Assay brane wall. The outer layer, made of polytetrafluoroethylene (PTFE), has a 5 µm pore size that assists the Cells were washed with PBS and pelleted. The cells were resuspended in 300 µl of extraction buffer (1% formation of blood vessels. The inner membrane of PTFE has a smaller pore size (0.4 µm) to prevent cell-Triton X-100 in glycylglycine buffer) and then centrifuged for 5 min at 350 × g. Supernatant (100 µl) was to-cell contact. An outer polyester mesh supports the added to 300 µl of glycylglycine buffer, 60 µl of 100 sue culture flasks were seeded with 2 × 10 6 PK cells ex-mM KPO 4 , pH 7.8, and 4 µl of 200 mM ATP. Samples pressing the reporter enzyme, luciferase, and left in were read on a luminometer using luciferin solution (1 identical culture conditions for 6 days. The cells were ml of 1 mM luciferin and 4 ml of glycylglycine buffer) then retrieved and quantified using a luciferase assay. to measure luciferase activity. To determine the lucifer-Luciferase assays have several advantages, high sensiase activity of encapsulated PK-luciferase cells, a stantivity, and linearity over 8 logs (8) . With a half-life dard curve from defined numbers of cells (1 × 10 4 , 1 × within cells of 3 h (27), it is suitable as a test for cell 10 5 , 1 × 10 6 , 1 × 10 7 ) was first generated. On day 35 the viability (24). An average of 1.35 × 10 7 cells could be capsules were retrieved, the cells inside were lysed, and found in the flasks while an average of only 3.3 × 10 6 the luciferase activity of the cells measured. The lucifercells could be found in the capsules after the culture ase activity of the transplanted cells was measured period. against the standard curve of known luciferase activity To test the survival and growth of these encapsulated generated at the time of transplantation.
cell lines in immunocompromised mice, NIT, CHO, and PK cells were placed in capsules and transplanted into RESULTS the peritoneum of SCID mice for 7 days. A slight in-A Foreign Body Reaction Against the TheraCyte  flammatory and fibrotic response was present surround-Device Occurs In Vivo ing the capsules containing each cell type ( Fig. 2D , E, Empty TheraCyte  capsules (prepared as per protocol F). Blood vessel formation could also be seen close to but no cells injected) were transplanted into the peritothe membrane wall. Histological analysis of NIT capneum of C57BL/6 mice for 35 days to investigate the sules revealed healthy tumor cells but also necrotic tisnature of the foreign body reaction to the device. At a sue ( Fig. 2D ). CHO cells within the immunoisolation macroscopic level the capsules showed excellent blood capsules grew as healthy tumor masses containing mivessel formation at the capsule surface. A thin layer of totic figures (Fig. 2E ). The tumor mass was 10-15 cells fibrotic material was found around the capsule and some thick in many sections of the capsules. Cell necrosis was organs had adhered to the device after 35 days. Histoapparent in the central regions of the capsules, presumlogical analysis of the empty capsules showed that an ably due to a lack of nutrient diffusion across the large inflammatory response had occurred against the Theravolume of live cells attached to the capsule wall. PK Cyte  device (Fig. 1) . A variety of myeloid cells could cell survival was restricted to 1-2 layers of cells and be detected at the capsule surface including macrowas accompanied with tissue debris (Fig. 2F ). As the phages/monocytes, eosinophils, neutrophils, and multipig is the favored donor species for xenotransplantation nucleate giant cells. Fibrotic material could be seen into humans, these cells were chosen for further transamong the membrane architecture of the device, as plantation studies involving the TheraCyte  capsule. could prominent blood vessel formation. These capsules can therefore elicit a nonspecific inflammatory response PK Cells in Immunoisolation Capsules Survive When by the host.
Transplanted Into SCID Mice but not C57BL/6 Mice To analyze PK cell growth in vivo, immunoisolation NIT, CHO, and PK Cells Can Survive In Vitro and In capsules containing PK cells were transplanted into Vivo in Immunoisolation Capsules SCID mice or normal C57BL/6 mice for 21 days. Histo-NIT, CHO, or PK cells were injected into an immulogical analysis of the devices showed survival of encapnoisolation capsule and left in culture in SMEM/1% sulated PK cells in SCID mice with several layers of NEAA/7% FCS for 4 days to assess cell survival under tumor cells attached to the walls of the capsules ( . Evidence of some cell death was apparent; howcapsule containing NIT cells showed that these cells reever, the surviving tissue remained healthy. A slight inmained healthy with mitotic figures present but some filtrate, similar to the foreign body response, could be evidence of cell death ( Fig. 2A ). CHO cells grew as a detected on the outer surface of the devices. In C57BL/ healthy tumor mass approximately 10 cell layers thick 6 mice a thick fibrous deposit surrounded many of the in some places (Fig. 2B) . Some mitotic figures could be devices. Histology revealed that the cells were destroyed detected. Healthy PK cells were also found in the their by day 21 (Fig. 3B) . The most striking feature of the capsules with some evidence of necrosis (Fig. 2C) .
histological sections was the intense inflammatory re-These cell lines can therefore survive inside the Therasponse surrounding the devices. This infiltrate consisted Cyte  device in conditions of high nutrient availability.
primarily of macrophage/monocytes and lymphocytes Comparison of the growth of PK cells in capsules or with few multinucleate giant cells, neutrophils, and eoin tissue culture flasks showed that tumor cell growth is restricted within the capsules. Five capsules and two tis-sinophils. Therefore, encapsulated xenogeneic PK cells survive when transplanted into immunodeficient SCID Unencapsulated PK Cells Do Not Survive in C57BL/6 Mice Treated With Anti-CD4 Antibody mice but not normal, immunocompetent mice.
To determine the survival of unencapsulated PK cells Anti-CD4 Antibody (GK1.5) Depletes in mice treated with anti-CD4 antibody, 1 × 10 7 unen-CD4 +ve Cells In Vivo capsulated PK cells were injected into the peritoneum of SCID mice, C57BL/6 mice, or GK1.5-treated C57BL/6 As PK cells did not survive in immunoisolation capmice (single 300 µg dose, day −1). Cells were retrieved sules in C57BL/6 mice, an experiment was designed to by peritoneal lavage and analyzed by flow cytometry on assess the effect of a systemic dose of anti-CD4 antidays 3 and 5. PK cells could be retrieved from SCID body (GK1.5) on encapsulated PK cell survival. To first mice (30% of original cells); however, very few cells assess the effect of purified monoclonal GK1.5 antibody survived in C57BL/6 mice or C57BL/6 mice given a on recipient CD4 +ve cells, C57BL/6 mice were treated IP dose of anti-CD4 antibody (<10% of original cells in with a single dose of 300 µg GK1.5 and monitored for both cases) ( Fig. 5 ). effects on cell numbers. This dose was based on previ-PK Cells Survive in Immunoisolation Capsules ous studies in our laboratory (18) . CD4 +ve cells are al-Transplanted Into Anti-CD4 Antibody-Treated most totally depleted from the peripheral blood of C57BL/6 Mice (Histological Analysis) treated mice by day 1 and remain so for at least 8 days after the initial injection of GK1.5 (Fig. 4) . CD4 +ve cells Capsules containing PK cells were transplanted into gradually repopulated the peripheral blood so that 70% SCID, C57BL/6, or C57BL/6 mice treated with GK1.5 of the initial CD4 +ve cells had returned by day 56 when on day −1. The SCID and C57BL/6 mice were killed on day 21 and the GK1.5-treated mice were killed on day the experiment was terminated. , and PK cells (C) were injected into the TheraCyte  device and placed in culture medium for 4 days. In each case the cells survived, with healthy layers of cells seen within the capsule lumen (H&E, A and C ×200, B ×100). (D, E, F) NIT cells (D), CHO cells (E), and PK cells (F) were injected into the TheraCyte  device and transplanted into immunodeficient SCID mice for 7 days. CHO cells grew much better than the other cell lines. The fast growth rate of these cells compromised nutrient diffusion resulting in death of cells in the middle of the capsule. NIT and PK cells also survived in these mice with healthy layers of cells attached to the capsule wall (H&E, D and F ×200, E ×100).
The amount of healthy tumor tissue in the capsules
cells. PK cell survival in some capsules was similar to that seen in capsules transplanted into SCID mice. The was determined using a scoring system on H&E histology sections (Fig. 6) .
severe inflammatory response surrounding the capsules in normal mice was reduced, but not abrogated, by anti-Capsules containing PK cells were rejected in C57BL/6 but survived in immunodeficient SCID mice.
CD4 antibody treatment. Inflammatory cells were present in the surrounding architecture of the device. Macro-Histology revealed that PK cell survival under the cover of anti-CD4 antibody was variable (Fig. 7) . All capsules, scopically, the anti-CD4 antibody did reduce the severe fibrotic response seen surrounding capsules from non-except one, contained a proportion of healthy tumor anti-CD4 antibody-treated mice. Therefore, a systemic vivo, PK cells that express a reporter enzyme, luciferase, dose of anti-CD4 antibody did improve the survival of were generated and placed into the capsules. Immunoi-PK cells in the TheraCyte  device, transplanted into norsolation capsules containing PK-luciferase cells were mal mice.
transplanted into SCID mice, C57BL/6 mice, or C57BL/ 6 mice for 35 days after a single dose of GK1.5 on Quantification of PK Cell Survival Using the day −1.
Luciferase Reporter Enzyme
PK-luciferase cells are destroyed in C57BL/6 mice, The histological assessment of cell survival in capas indicated by the low cell number retrieved from these sules transplanted into anti-CD4 treated mice was varicapsules after 35 days (Fig. 8) . PK-luciferase cells placed able and at best semiquantitative. In an attempt to quaninto SCID mice survived significantly better than cells tify the number of encapsulated PK cells surviving in transplanted into normal C57BL/6 mice (p < 0.05, Mann- tions of grafted capsules were scored for cell survival accordanti-CD4 antibody. C57BL/6 mice were given one IP dose of ing to criteria listed. 0 = no living tissue; 1 = scattered viable 300 µg of GK1.5 (anti-mouse CD4 antibody). CD4 +ve cell cells/layers of cells; 2 = 1-2 complete layers of viable cells; numbers were determined by total white blood cell counts and 3 = >3 layers of viable cells. Encapsulated PK cells do not FACS analysis using an anti-CD4-PE antibody. Each data survive in normal mice but do in both SCID mice and antipoint represents the mean ± SD of 5 mice.
CD4 antibody-treated mice.
Whitney test). Capsules from GK1.5-treated mice also into immunodeficient mice. However, the TheraCyte  survived significantly better than cells in C57BL/6 mice device cannot protect xenogeneic cells from immune re-(p < 0.05, Mann-Whitney test). Therefore, cell survival jection in normal mice, despite the lack of direct cell in vivo could be detected using a luciferase assay and contact between the infiltrating and encapsulated cells. confirmed the histological findings that depletion of the A single systemic dose of anti-CD4 antibody improved CD4 +ve lymphoid population results in increased encapencapsulated xenogeneic cell survival, suggesting that sulated xenogeneic cell survival.
CD4 +ve lymphocytes are central to the initiation of a re-DISCUSSION jection response. The same dose of antibody did not improve the survival of unencapsulated cells in normal Using the TheraCyte  device, encapsulated allogeneic and xenogeneic cells survived when transplanted mice. The transfection of cells with a luciferase con- struct allows the quantification of encapsulated cell sur-Brauker and colleagues argue that a cellular response is beneficial to neovascularization of the capsule (5), it is vival after an extended period in vivo.
A foreign body reaction to the TheraCyte  membrane possible that the presence of a nonspecific cellular infiltrate could be harmful to the encapsulated cells. It is occurs after placing capsules into mice. This reaction was typical of that previously reported by Tang and col-essential that the membrane pores be made large enough to allow nutrients such as glucose, albumin, and growth leagues, who showed that synthetic biomaterials acquire a layer of denatured host proteins on the surface after factors, as well as oxygen, to reach the encapsulated cells. However, it is not possible to prevent oxygen radi-transplantation into the host (25) . This protein layer dictates the response of phagocytic cells to the implant. A cals, complement, and antibody from also entering the capsule. The infiltrating phagocytes secrete harmful ox-variety of myeloid cells, including macrophages/monocytes, multinucleate giant cells, eosinophils, and neutro-ides, such as nitric oxide, or cytokines that could inhibit the growth of, or destroy, the grafted cells. Natural or phils, were detected at the site of the TheraCyte  device. Fibrotic material was also deposited within the outer induced antibodies, in conjunction with components of the complement system, could also mediate the destruc-membrane architecture. Tibell and coworkers reported massive fibrosis surrounding TheraCyte  capsules trans-tion of encapsulated cells. Xenogeneic cells in the TheraCyte  devices survive planted with allogeneic tissue into humans (28). While Figure 8 . Analysis of PK cell survival in TheraCyte  capsules using the luciferase reporter gene system. PK cells (2 × 10 6 ) were placed into TheraCyte  capsule and transplanted into the peritoneal cavity of appropriate mice for 35 days. The capsules were retrieved and luciferase production by the cells determined using an in vitro luciferase assay. A single point represents a capsule from each mouse and a bar represents the average of each group.
in immunodeficient SCID mice but not normal C57BL/6 and porcine islets after capsule transplantation (14). Within 2-6 weeks after transplantation, sera collected mice. The survival of PK cells in SCID mice suggests that these capsules can sustain physiological function for from the transplanted rats showed strong reactivity towards porcine and canine islets by immunocytochemis-the encapsulated cells in vivo. SCID mice are deficient in T and B lymphocytes but have normal numbers of try. Others have not shown direct evidence of antigen shedding but have speculated that an indirect mechanism functional myeloid cells (2). This implies that lymphoid cells are central for the destruction of encapsulated tis-involving shed antigen is responsible for the inflammatory response against encapsulated cells (6,16,29). Like sue. In normal mice a heavy cellular infiltrate occurs around capsules containing xenogeneic cells. This in-these groups, the results presented show that an intense infiltrate surrounds capsules containing xenogeneic cells, filtrate contains macrophage/monocytes, lymphocytes, eosinophils, neutrophils, and multinucleate giant cells, but not capsules that are empty. The host must therefore be activated against the encapsulated cells by recogni-cells that must be recruited to the site of the implant. How does recognition of foreign encapsulated cells oc-tion of shed foreign antigen. While many cells are present in the infiltrate sur-cur so that infiltrating cells can be recruited to the graft site? Presentation and recognition of foreign antigen can rounding rejecting encapsulated cells, CD4 +ve T cells have been shown to have a central role in the initiation occur by two mechanisms: direct and indirect. During direct presentation, the TCR recognizes MHC antigens of the inflammatory response. Weber and coworkers were the first to report the role of CD4 +ve T cells in the presented to host T cells by donor antigen-presenting cells. Foreign antigens can also be processed and pre-destruction of microencapsulated islet xenografts (29). Administration of anti-CD4 antibody, GK1.5, signifi-sented to the host T cells by host antigen-presenting cells (indirect presentation). As the implanted and infil-cantly prolonged the survival of encapsulated canine and rat islets transplanted into NOD mice. Loudovaris and trating cells cannot associate directly, then the indirect mechanism becomes the primary method of antigen rec-colleagues also concluded that CD4 +ve T cells could mediate the destruction of xenografts in diffusion chambers ognition. If this is the case, xenogeneic antigen must be shed from inside the capsule where it travels through the without the need for CD8 +ve T cells or B cells (16) . In that study, monkey kidney cell (COS) survival in diffu-pores and is phagocytosed and processed by the host antigen-presenting cells. Antigen could be shed from the sion chambers was significantly improved when CD4 +ve T cells were absent. The exact effector mechanisms that cell surface of live cells or be released by damaged or dying cells. The most convincing evidence that antigen are involved with the destruction of encapsulated tissue are still unknown. As with the rejection of nonencapsu-is shed from inside immunoisolation capsules is the formation of a humoral response in rats transplanted with lated xenogeneic tissue, a variety of cells secreting cytokines, antibody, cytotoxic molecules, and oxygen radi-encapsulated xenogeneic cells. Lanza and colleagues reported that a humoral response developed to both canine cals are likely to be involved. These molecules may act
